NCT00104975View on ClinicalTrials.gov

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Chronic Myeloproliferative DisordersLeukemiaLymphomaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Interventions
BIOLOGICAL

alemtuzumab

BIOLOGICAL

therapeutic allogeneic lymphocytes

DRUG

fludarabine phosphate

DRUG

melphalan

DRUG

tacrolimus

DRUG

thiotepa

PROCEDURE

peripheral blood stem cell transplantation

Trial Locations (1)

06520-8028

Yale Cancer Center, New Haven

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Yale University

OTHER

NCT00104975 - Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | Biotech Hunter | Biotech Hunter